{"entity":{"id":"emavusertib","kind":"drug","name":"Emavusertib","aka":["CA-4948"],"tldr":"Emavusertib is an oral serine/threonine kinase inhibitor from Curis, Inc., in registered phase 2 trials for chronic lymphocytic leukaemia, brain and spinal cord tumours.","summary":"Emavusertib is listed on ClinicalTrials.gov as an intervention in 2 registered phase 2 trials sponsored by Curis, Inc., in chronic lymphocytic leukaemia, brain and spinal cord tumours. A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Emavusertib","url":"https://clinicaltrials.gov/search?intr=Emavusertib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["cll","brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["curis"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07271667","nct03328078"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral serine/threonine kinase inhibitor","mechanism":"A serine/threonine kinase inhibitor: the name stem -sertib marks a small molecule that blocks a kinase in this family.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/emavusertib/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"},{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"company":[{"id":"curis","kind":"company","name":"Curis","route":"/companies/curis/"}],"trial":[{"id":"nct07271667","kind":"trial","name":"A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies","route":"/trials/nct07271667/"},{"id":"nct03328078","kind":"trial","name":"CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)","route":"/trials/nct03328078/"}]}}